GENINVO provides a unique combination of expertise in Life Sciences, leading-edge technologies, and software development. That enables us to provide innovative and transformative products, solutions, and services. During the COVID-19 pandemic, we are supporting our clients who develop, screen, and test drugs to find a treatment for this disease as fast as possible. We are proud to be a part of the solution.
We see the impact of innovation up close daily, from our client’s perspective. We strive to develop efficient, innovative products and solutions for our clients to make the drug development process smarter, faster, and more cost-effective. Innovation is an essential element of our mission and success for clients. We support their journey, working collaboratively to understand the needs of their systems and processes and their current challenges within these areas.
We have a strong pipeline of innovative products, built using advanced technologies to support the unmet gaps and launched state-of-the-art products, such as Shadow and DocQC. We continue to build new, robust products. ApoGI is an example of an integrated automation platform that leverages AI (artificial intelligence) and ML (machine learning) to focus on standards in metadata management. It streamlines processes and the generation of artefacts, typically associated with the clinical study lifecycle.
As the Director of Innovation Solutions and Strategy, Ramesh Venkataramana said, “With many years of experience in various pharma organizations, there are gaps within the current landscape of Process/Systems/Tools usage within the respective organizations’ current legacy drug development portfolio. From study setup to closure, pharma companies look for futuristic, long-term, and efficient to deliver on time with quality on an advanced platform within a regulated environment. GENINVO has a like-minded group of talented people who understand the client’s perspective and develop innovative solutions to address these gaps sooner.”
We understand the demand for people with knowledge and skills in AI and ML exceeds the supply. We continue searching for talented, experienced professionals to join us.
At this critical time as COVID-19 spreads around the globe, we consider the safety of all employees and advised them to work from home. Regardless of the situation, the product development timeline is still on track. This shows the dedication of our employees and their commitment, while allowing employees to balance work and personal time spent. We support communities around the Bloomington-Normal area recently providing hundreds of lunches to a nearby school and are ready to support many more. Over the next few months, we will continue to invest advanced technology to build strong products for the Life Sciences domain while scaling to other industries. Email us with questions at firstname.lastname@example.org.